Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04572763 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04572763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 8, 2021
Completion date
July 29, 2026
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma